Phoenix Health Services LLC

phxhealthohio.com

Phoenix Health Services, a small family owned and operated healthcare company, operates two skilled nursing facilities in Northeast Ohio. Sunrise Pointe Nursing & Rehab in Maple Heights and Windsong Nursing & Rehab in Akron. Check out our website to learn more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

news image

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

news image

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More

MEDTECH

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

news image

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More
news image

CELL AND GENE THERAPY

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More
news image

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More
news image

MEDTECH

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More
news image

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More